Table 2:

Frequency of study outcomes with anti-TNF or vedolizumab in patients with inflammatory bowel diseases 60 years or older

Outcome	Anti-TNF (n=131)	Vedolizumab (n=103)	p-value
Remission:
At 3 months	65(50%)	39(38%)	0.07
At 6 months	65(54%)	46(45%)	0.23
At 12 months	61(58%)	47(54%)	0.63
Need for IBD surgery at 1 year	14(11%)	10(10%)	0.78
Need for IBD hospitalization at 1 year	26(20%)	13(13%)	0.12
Infection (within 1 year)	20%	17%	0.54
Type of infection	(n = 24)	(n = 17)
Pneumonia	7(29%)	4(24%)
Sepsis	2(8%)	2(12%)
UTI	3(13%)	0%
Abscess	4(17%)	3(18%)
C difficile	5 (21%)	1 (6%)
CMV	1 (4%)	0 (0%)
Dental infection	1 (4%)	0 (0%)
Shingles	1 (4%)	0 (0%)
URI	0 (0%)	5 (29%)
Fever (unspecified)	0 (0%)	1 (6%)
Gastroenteritis	0 (0%)	2 (12%)
Skin cancer	1(0.8%)	1(1.0%)	0.86
Other cancers	4(3%)	1(1%)	0.27
Reason for cessation	(n = 80)	(n = 37)
Infusion / Allergic reaction	16(20%)	2(5%)
Infection	9(11%)	5(14%)
Cancer	4(5%)	1(3%)
Heart failure	1(1%)	0(0%)
Other	50(63%)	29(78%)